PHASE II CLINICAL TRIAL WITH CAELYX MONO-CHEMOTHERAPY IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES STAGE IIb, IVa AND IVb WITH OR WITHOUT PREVIOUS CHEMOTHERAPY.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-003728-36-IT

Enrollment

Registered

2005-08-01

Start date

2004-12-10

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADVANCED STAGE CUTANEOUS T CELL LYMPHOMA.

Interventions

Trade Name: CAELYX*IV 1 FL 25 ML 2 MG/ML Product Name: NA Product Code: NA Pharmaceutical Form: Solution for infusion INN or Proposed INN: Doxorubicin CAS Number: 25316-40-9 Concentration unit: mg mil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026